Quest Diagnostics stock edges lower ahead of the open after a 0.7 percent drop
Published on 09/10/2026 at 03:35 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Quest Diagnostics stock closed at USD 235.50 on the New York Stock Exchange on September 8, 2026, down 0.69 percent from the previous close of USD 237.14 per Nasdaq data. The move left the shares only a few percent below their 52-week high of USD 247.19 and well above the 52-week low of USD 171.18, keeping the recent uptrend largely intact. On the same day, the Dow Jones Industrial Average fell 1.2 percent to 52,786.07, underscoring a weak broader market backdrop for Quest Diagnostics shares.
September 8, 2026 in numbers
Quest Diagnostics Incorporated (ISIN US74834L1008, NYSE: DGX) recorded a closing price of USD 235.50 on September 8, 2026, with a decline of 0.69 percent against a prior close of USD 237.14, according to Nasdaq quote data. Intraday, the stock traded within a range that left the close comfortably above the documented 52-week low of USD 171.18 and only several percent below the 52-week high of USD 247.19 reported in early September 2026 by MarketBeat and other market overviews. As MarketBeat noted in a recent trading update, Quest Diagnostics shares were described as trading around USD 235.78 with a 52-week range between USD 171.18 and USD 247.19, highlighting that the stock remains near the upper end of its one-year band.MarketBeat In the broader market, the Dow Jones Industrial Average closed at 52,786.07 after a 1.2 percent loss, indicating that Quest Diagnostics stock slipped in a session marked by general equity weakness.Yahoo Finance
Apple Health labs tie-up in focus today
Today, attention turns to a newly announced partnership that links Quest Diagnostics more closely with Apple’s Health app ecosystem. Apple disclosed that users in the United States will be able to schedule and purchase new lab panels featuring more than 50 key biomarkers for USD 119 directly through the Health app at approximately 2,000 Quest Diagnostics locations, integrating Quest’s lab services into Apple’s digital health offering.Apple A detailed overview of the new labs feature described how US users can book and buy a blood panel covering more than 50 biomarkers for USD 119 at about 2,000 Quest Diagnostics locations, reinforcing the operational role Quest plays in the rollout.The Mac Observer Quest Diagnostics itself highlighted the partnership in a newsroom communication on September 9, 2026, underlining that Apple Health app users will be able to order labs from Quest Diagnostics, a development that could influence investor sentiment heading into today’s session.Quest Diagnostics
